)
Visual
test
Atomo Diagnostics
Atomo Diagnostics (AT1) investor relations material
Atomo Diagnostics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Jan, 2026
Executive summary
Quarterly revenue reached AUD 1.5 million (up 121% QoQ), driven by strong HIV self-test and OEM Pascal sales, with significant orders from Lumos/FebriDx and new international customers.
HIV self-test demand remained robust in Africa and expanded into Australia, New Zealand, Eastern Europe, and Southeast Asia, supported by a $500k order and government initiatives.
Exclusive global licensing agreement signed for a novel ALT liver function test, with initial use in drug trials and ongoing evaluation in the US.
Operational expansion underway, including increased blister production capacity in Sydney to 12-15 million units per annum.
Net cash from operating activities was positive at A$171,000 for the quarter, with cash and cash equivalents rising to A$3,512,000.
Financial highlights
Quarterly revenue was AUD 1.5 million, more than doubling the previous quarter, with gross margin steady at 40%.
Customer receipts totaled AUD 1.17 million, and government grants and R&D rebates contributed over AUD 1 million.
Cash on hand at quarter end was just over AUD 3.5 million, with no debt.
Net cash burn from operating activities was less than AUD 1 million for the first half; the quarter was cash positive.
Operating expenses for the quarter were AUD 1.5 million, tightly controlled to focus on growth.
Outlook and guidance
Continued growth expected in HIV and OEM Pascal segments, with new products anticipated to come to market.
Clinical trials for the syphilis test are planned to start within the next 3-6 months, with regulatory submission for the liver test to follow review of clinical data.
Decision on FebriDx CLIA waiver expected in early 2026, supporting further operational expansion.
Revenue growth is expected to continue without a corresponding rise in operating expenses.
Quantify new OEM customer initial orders
Liver test: timeline for drug monitoring regulatory submission
Syphilis test: next steps post tech transfer and trials
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- MAERSK
Strong FY25 results with robust cash returns, but FY26 outlook cautious amid market headwinds. - VATN
Record profit, higher dividend, CET1 at 17.2%, and CHF 75m share buyback announced. - MATAS
Record Q3 revenue growth led by Matas, but KICKS declined as consumers traded down. - CZWI
Q2 2025 net income was $3.3M, with margin gains and a 5% buyback authorized. - MILDEF
Record-breaking growth and profitability in 2025, fueled by acquisitions and strong order intake. - MYCR
Q4 sales down 2%, order intake down 19%, but record full-year sales and four acquisitions. - VF
Underlying EBIT up 81% to SEK 30.9 bn; profit down 41% amid divestments and major investments. - ADDT
Earnings and margins rose, acquisitions accelerated, and outlook remains positive. - NCC
Record profits in core segments, major impairment, dividend maintained, outlook positive. - 7004
Order intake and sales rose, but losses and technical issues led to lower profit forecasts.
Atomo Diagnostics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Atomo Diagnostics Limited provides products in the areas of cancer, infectious diseases, and cardiovascular ailments. Its tests include Visca for diagnosing liver cancer and liver fibrosis/cirrhosis; MammaScreen for early breast cancer detection through measurements of plasma proteins (by testing blood); Chlamydia Screen for the screening or confirmation of Chlamydia trachomatis infections; HIV-1Virology Test System for the qualitative detection of antibodies to human immunodeficiency virus type 1 (HIV-1); and AtomoRapid Malaria Test that detects malaria infection in whole blood samples. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage